Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico…
Read More...
Read More...